Abstract:Introduction Among various lupus renal vascular changes, thrombotic microangiopathy (TMA) presented with the most severe clinical manifestations and high mortality. The pathogenesis of TMA in systemic lupus erythematosus (SLE) was complicated. The aim of this study was to assess clinical manifestations, laboratory characteristics, pathological features and risk factors for clinical outcomes of lupus nephritis patients co-existing with renal TMA in a large cohort in China. Methods Clinical and renal histopathological data of 148 patients with biopsy-proven lupus nephritis were retrospectively analyzed. Serum complement factor H, A Disintegrin and Metalloprotease with Thrombospondin type I repeats 13 (ADAMTS-13) activity, antiphospholipid antibodies and C4d deposition on renal vessels were further detected and analyzed. Results In the 148 patients with lupus nephritis, 36 patients were diagnosed as co-existing with renal TMA based on pathological diagnosis. Among the 36 TMA patients, their clinical diagnoses of renal TMA were as followings: 2 patients combining with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 2 patients combining with anti-phospholipid syndrome, 2 patients with malignant hypertension, 1 patient with scleroderma and the other 29 patients presenting with isolated renal TMA. Compared with the non-renal TMA group, patients with renal TMA had significantly higher urine protein (7.09 ± 4.64 vs. 4.75 ± 3.13 g/24h, P = 0.007) and serum creatinine (159, 86 to 215 vs. 81, 68 to 112 μmol/l, P <0.001), higher scores of total activity indices (AI) ( P <0.001), endocapillary hypercellularity ( P <0.001), subendothelial hyaline deposits ( P = 0.003), interstitial inflammation ( P = 0.005), glomerular leukocyte infiltration ( P = 0.006), total chronicity indices (CI) ( P = 0.033), tubular atrophy ( P = 0.004) and interstitial fibrosis ( P = 0.018). Patients with renal TMA presented with poorer renal outcome ( P = 0.005) compared with the non-TMA group. Renal TMA (hazard ratio (HR): 2.772, 95% confidence interval: 1.009 to 7.617, P = 0.048) was an independent risk factor for renal outcome in patients with lupus nephritis. The renal outcome was poorer for those with both C4d deposition and decreased serum complement factor H in the TMA group ( P = 0.007). Conclusions There were various causes of renal TMA in lupus nephritis. Complement over-activation via both classical and alternative pathways might play an important role in the pathogenesis of renal TMA in lupus nephritis.

Plasmapheresis is Associated with Better Renal Outcomes in Lupus Nephritis Patients with Thrombotic Microangiopathy

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Early-stage predictors for treatment responses in patients with active lupus nephritis.

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy

Plasmapheresis combined with rituximab treatment of a case of thrombotic thrombocytopenic purpura with Sjögren syndrome and renal impairment: A case report

Efficacy of individualized rituximab as the rescue therapy for active lupus nephritis with acute kidney injury

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Characteristics and Renal Survival of Patients with Lupus Nephritis with Glomerular Immunoglobulin G4 Deposition: a Single-Centre Retrospective Analysis.

Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation

Clinicopathological Features and Outcomes of SLE Patients with Renal Injury Characterised by Thrombotic Microangiopathy.

Combination therapy of double filtration plasmapheresis and glucocorticoid in severe lupus nephritis

Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients

The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

The Spectrum of Renal Thrombotic Microangiopathy in Lupus Nephritis

Application of Plasmapheresis in Treating the Antibody-Mediated Acute Rejection after Kidney Transplantation

TMA Secondary to SLE: Rituximab Improves Overall but Not Renal Survival

Clinical Characteristics and Prognosis of Diffuse Proliferative Lupus Nephritis with Thrombotic Microangiopathy.

Plasmapheresis in ANCA-Associated Vasculitis with Active Kidney Involvement in the United States (2016-2020): A Cross-Sectional Study

Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis